Metabolic Checkpoints: Novel Avenues for Immunotherapy of Cancer

Immunotherapy

Novel immunotherapy strategies for hepatobiliary cancers

Immunotherapy.

DeLeon TT, Zhou Y, Nagalo BM, Yokoda RT, Ahn DH, Ramanathan RK, Salomao MA, Aqel BA, Mahipal A, Bekaii-Saab TS, Borad MJ

doi: 10.2217/imt-2018-0024.

RECOMMENDED

Immunotherapy

Development of a novel class of interleukin-2 immunotherapies for metastatic cancer

doi: smw.2019.14697.

Immunotherapy

Targeting T Cell Metabolism for Improvement of Cancer Immunotherapy

Front Oncol.

Le Bourgeois T, Strauss L, Aksoylar HI, Daneshmandi S, Seth P, Patsoukis N, Boussiotis VA

doi: 10.3389/fonc.2018.00237.

Immunotherapy

Immunotherapy in Gastrointestinal Cancers

Biomed Res Int.

Procaccio L, Schirripa M, Fassan M, Vecchione L, Bergamo F, Prete AA, Intini R, Manai C, Dadduzio V, Boscolo A, Zagonel V, Lonardi S

doi: 10.1155/2017/4346576.

Melanoma and Skin CancerImmunotherapy

Identification of essential genes for cancer immunotherapy

Nature.

Patel SJ, Sanjana NE, Kishton RJ, Eidizadeh A, Vodnala SK, Cam M, Gartner JJ, Jia L, Steinberg SM, Yamamoto TN, Merchant AS, Mehta GU, Chichura A, Shalem O, Tran E, Eil R, Sukumar M, Guijarro EP, Day CP, Robbins P, Feldman S, Merlino G, Zhang F, Restifo NP

doi: 10.1038/nature23477.

Critical features and challenges associated with imaging in patients undergoing cancer immunotherapy

Crit Rev Oncol Hematol.

Solinas C, Porcu M, Hlavata Z, De Silva P, Puzzoni M, Willard-Gallo K, Scartozzi M, Saba L

doi: 10.1016/

The tumour glyco-code as a novel immune checkpoint for immunotherapy

Nat Rev Immunol.2018 Mar;18(3):204-211.doi: 10.1038/nri.2018.3.

RodrÍguez E, Schetters STT, van Kooyk Y

doi: 10.1038/nri.2018.3.

T Cells

Cancer immunotherapy with check point inhibitor can cause autoimmune adverse events due to loss of Treg homeostasis

Semin Cancer Biol.

Kumar P, Saini S, Prabhakar BS

doi: 10.1016/j.semcancer.

Melanoma and Skin CancerImmunotherapy

Polymeric nanoparticles encapsulating novel TLR7/8 agonists as immunostimulatory adjuvants for enhanced cancer immunotherapy

Biomaterials

Kim H, Niu L, Larson P, Kucaba TA, Murphy KA, James BR, Ferguson DM, Griffith TS, Panyam J

doi: 10.1016/j.biomaterials.

Related content

Novel immunotherapy strategies for hepatobiliary cancers

Development of a novel class of interleukin-2 immunotherapies for metastatic cancer

Targeting T Cell Metabolism for Improvement of Cancer Immunotherapy

Immunotherapy in Gastrointestinal Cancers

Identification of essential genes for cancer immunotherapy

Critical features and challenges associated with imaging in patients undergoing cancer immunotherapy

The tumour glyco-code as a novel immune checkpoint for immunotherapy

Cancer immunotherapy with check point inhibitor can cause autoimmune adverse events due to loss of Treg homeostasis

Polymeric nanoparticles encapsulating novel TLR7/8 agonists as immunostimulatory adjuvants for enhanced cancer immunotherapy